TGFB2 and Graves ophthalmopathy: In fact, we recently developed a 3D cell drop culture method as an in vivo model for Graves’ orbitopathy [25], deepening of the upper eyelid sulcus (DUES) [17,18], and as a POAG TM model using TGF-β2-treated HTM cells [19], and we simultaneously recognized that those models can be used for screening drug efficacies.